Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- Conditions
- Non Small Cell Lung CancerSolid Tumors, AdultLung AdenocarcinomaLung Cancer
- Interventions
- Registration Number
- NCT05887492
- Lead Sponsor
- Tango Therapeutics, Inc.
- Brief Summary
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.
The main question\[s\] it aims to answer are:
* the recommended dose for Phase 2
* to evaluate the safety and tolerability of the combination therapy
* to determine the pharmacokinetics of TNG260
* to evaluate the initial antineoplastic activity
Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
- Detailed Description
This is a first-in-human Phase 1/2, open-label, multicenter, dose-escalation and expansion study designed to determine the maximum tolerated dose and recommended phase 2 dose(s) and evaluate the safety and tolerability, pharmacokinetics, and antineoplastic activity of escalating oral doses of TNG260 when administered with a standard dose of pembrolizumab in participants with locally advanced or metastatic STK11 mutated solid tumors.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 126
- Is ≥18 years of age at the time of signature of the main study ICF.
- Has ECOG performance status of 0 or 1.
- Has measurable disease based on RECIST v1.1.
- All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method
- Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor.
- Adequate organ function/reserve per local labs
- Adequate liver function per local labs
- Adequate renal function per local labs
- Negative serum pregnancy test result at screening
- Written informed consent must be obtained according to local guidelines
- Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients
- Uncontrolled intercurrent illness that will limit compliance with the study requirements
- Active infection requiring systemic therapy
- Currently participating in or has planned participation in a study of another investigational agent or device
- Impairment of GI function or disease that may significantly alter the absorption of oral TNG260
- Active prior or concurrent malignancy.
- Central nervous system metastases associated with progressive neurological symptoms
- Current active liver disease from any cause
- Clinically relevant cardiovascular disease
- A female patient who is pregnant or lactating
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Dose Expansion in Advanced or Metastatic Solid Tumors TNG260 Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab Dose Expansion in NSCLC with KRAS Mutation Pembrolizumab Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab Dose Expansion in NSCLC with KRAS Mutation TNG260 Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab Dose Expansion in NSCLC with KRAS Wild type TNG260 Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab Dose Escalation TNG260 Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD Dose Expansion in Advanced or Metastatic Solid Tumors Pembrolizumab Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab Dose Escalation Pembrolizumab Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD Dose Expansion in NSCLC with KRAS Wild type Pembrolizumab Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab
- Primary Outcome Measures
Name Time Method Measure antitumor activity using RECIST 1.1 (Phase 2 only) 12 weeks To assess antineoplastic activity of TNG260 when administered in combination with pembrolizumab in participants with locally advanced unresectable or metastatic STK11-mutated solid tumors by measuring ORR, DOR, and PFS by RECIST 1.1
Determine the MTD and RP2D(s) (Phase 1 only) 42 days To determine the MTD and RP2D(s) of TNG260 when administered in combination with pembrolizumab
- Secondary Outcome Measures
Name Time Method Measure antitumor evidence of TNG260 + pembrolizumab antineoplastic activity by RECIST 1.1 (Phase 1 only) 12 weeks To assess antineoplastic activity of TNG260 when administered in combination with pembrolizumab in participants with locally advanced unresectable or metastatic STK11-mutated solid tumors by measuring ORR, DOR, and PFS by RECIST 1.1
Characterize Area Under the Curve (AUC) of TNG260 37 days Measure the plasma concentration versus time curve (AUC) of TNG260 alone and when administered in combination with pembrolizumab
To measure changes in histone acetylation when administered with TNG260 12 weeks Measure changes in levels of histone acetylation in blood and/or tumor tissue, on study treatment relative to pre-treatment
Characterize the time to achieve Time to Maximal Concentration (Tmax) of TNG260 37 days To characterize the Tmax by measuring the plasma concentrations versus time of TNG260 alone and when administered in combination with pembrolizumab
Characterize Terminal Half-life (T1/2) of TNG260 37 days To characterize the T1/2 by measuring the plasma concentrations versus time of TNG260 alone and when administered in combination with pembrolizumab
Characterize pembrolizumab concentrations when administered with TNG260 43 days To characterize the pre treatment and trough concentration levels of pembrolizumab when administered in combination with TNG260
Safety and tolerability of TNG260 by CTCAE 5.0 42 days To evaluate the safety and tolerability of TNG260 when administered as single agent and in combination with pembrolizumab by measuring the incidence, nature, and severity of AE and SAE graded according to CTCAE v5.0
Characterize Maximum Observed Plasma Concentration (Cmax) of TNG260 37 days To characterize the Cmax by measuring the plasma concentrations versus time of TNG260 alone and when administered in combination with pembrolizumab
Trial Locations
- Locations (10)
UCLA Hematology/Oncology
🇺🇸Santa Monica, California, United States
SCRI at HealthOne
🇺🇸Denver, Colorado, United States
Florida Cancer Specialists
🇺🇸Sarasota, Florida, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
START MidWest
🇺🇸Grand Rapids, Michigan, United States
New York University Langone Health
🇺🇸New York, New York, United States
Sarah Cannon Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
NEXT Oncology Virginia
🇺🇸Fairfax, Virginia, United States